Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of cancer and immune-mediated diseases. The company’s proprietary Superkine platform is designed to enhance the therapeutic potential of cytokines through precision-engineered biologics intended to improve efficacy while reducing toxicity.

Topics discussed include the company’s clinical development programs, technology platform, business strategy, growth initiatives, market opportunities, and long-term outlook.

This company webcast was recorded during the Lytham Partners Spring 2026 Investor Conference.